Developer docs
API playgroundTry for free, no card

Search company profiles

Gotham Therapeutics

Full company profile

uuid0005ksc

Namestring
Gotham Therapeutics
Websiteurl
gothamtx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Gotham Therapeutics is a preclinical-stage biotechnology company founded in 2017 and headquartered in New York that is building a drug discovery platform around epitranscriptomics — the systematic study of chemical modifications to RNA and the enzymes that install, remove, and read them. The company's stated mission is to discover a novel class of small-molecule therapeutics that modulate RNA-modifying enzymes, an emerging therapeutic modality with potential applications across oncology, neurological, and inflammatory diseases.

Operationally, Gotham is structured as a private, venture-backed research organization with a small scientific team (1-10 employees in the firmographic record). The company's underlying technology centers on biochemical and cellular assays against RNA-modifying enzymes, supported by medicinal chemistry to develop selective chemical matter. Because no products, clinical assets, or platform offerings are listed in the available data, the company appears to be in the early discovery phase, with its pipeline still upstream of IND-enabling studies.

Gotham's business model is consistent with a venture-backed preclinical biotech: capital is raised in discrete equity rounds to fund internal R&D, with the long-term monetization path being out-licensing of programs, co-development partnerships with larger pharmaceutical companies, or an eventual acquisition. Its only documented financing is a $54 million Series A closed in October 2018, led by Versant Ventures with Forbion Capital Partners and SR One as co-investors. Leadership consists of Founder Samie Jaffray and CEO Lee Babiss. The company has no disclosed revenue, pricing, partnerships, or commercial milestones in the available source material.

Short descriptiontext

Gotham Therapeutics is a preclinical-stage, New York-based biotechnology company founded in 2017 that is developing small-molecule drugs targeting RNA-modifying enzymes (epitranscriptomics) for therapeutic use.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
epitranscriptomic drug discovery, RNA-modifying enzyme inhibitors, small molecule therapeutics, novel drug class, biotech drug development
Industry3 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Epitranscriptomic Therapeutics
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Gotham Therapeutics is a biotechnology company focused on discovering a novel drug class that targets the epitranscriptomics machinery — the enzymes and readers responsible for chemical modifications of RNA. The company identifies and develops small-molecule therapeutics against RNA-modifying enzymes for the treatment of disease, primarily operating in early-stage drug discovery.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The source data does not relate to Gotham Therapeutics. The domain gothamtx.com is a slot gambling review content website acquired by X41 Group in 2024, previously associated with a Therapeutics company of the same name. No product or service offerings for Gotham Therapeutics were found in the source material.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor also developing small-molecule inhibitors of RNA-modifying enzymes (notably METTL3 and other m6A writers), with a substantially larger Series B/C financing base.

TypeEmerging player
Description

Develops small molecules that modulate RNA splicing and RNA biology; overlapping modality of small-molecule RNA targeting with multiple pharma partnerships.

TypeDirect peer
Description

UK-based epitranscriptomics company developing first-in-class small molecules against RNA-modifying enzymes, the closest international analogue to Gotham's scientific focus.

TypeEmerging player
Description

Pursues therapeutic modulation of RNA modifications and biomolecular condensates in cancer; partial mechanistic overlap with Gotham's epitranscriptomic strategy.

TypeBroad incumbent
Description

Public epigenomic programming company using engineered mRNA-encoded transcription factors; a broader incumbent in the gene-expression modulation space adjacent to epitranscriptomics.

TypeBroad incumbent
Description

Public chromatin-regulation company targeting dysregulated gene-expression machinery in cancer; adjacent to Gotham's RNA-biology strategy via shared interest in gene-expression modulators.

TypeEmerging player
Description

Discovers small molecules that target RNA structures and RNA-protein interactions; complementary rather than identical mechanism but competing for the same RNA-targeting BD budget.

TypeDirect peer
Description

Targets RNA-modifying proteins (e.g., METTL3) for cancer therapy; one of the original entrants into the small-molecule epitranscriptomics space.

TypeDirect peer
Description

Emerging epitranscriptomics player focused on small-molecule modulators of RNA-modifying enzymes in oncology and other indications.

10Expansion Therapeutics
TypeEmerging player
Description

Develops small-molecule RNA-targeting therapeutics, primarily for repeat-expansion disorders; comparable RNA-biology drug-discovery platform approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gotham Therapeutics

Epitranscriptomic Therapeuticsgothamtx.com

Gotham Therapeutics is a preclinical-stage, New York-based biotechnology company founded in 2017 that is developing small-molecule drugs targeting RNA-modifying enzymes (epitranscriptomics) for therapeutic use.

What Gotham Therapeutics does

Gotham Therapeutics is a preclinical-stage biotechnology company founded in 2017 and headquartered in New York that is building a drug discovery platform around epitranscriptomics — the systematic study of chemical modifications to RNA and the enzymes that install, remove, and read them. The company's stated mission is to discover a novel class of small-molecule therapeutics that modulate RNA-modifying enzymes, an emerging therapeutic modality with potential applications across oncology, neurological, and inflammatory diseases.

Operationally, Gotham is structured as a private, venture-backed research organization with a small scientific team (1-10 employees in the firmographic record). The company's underlying technology centers on biochemical and cellular assays against RNA-modifying enzymes, supported by medicinal chemistry to develop selective chemical matter. Because no products, clinical assets, or platform offerings are listed in the available data, the company appears to be in the early discovery phase, with its pipeline still upstream of IND-enabling studies.

Gotham's business model is consistent with a venture-backed preclinical biotech: capital is raised in discrete equity rounds to fund internal R&D, with the long-term monetization path being out-licensing of programs, co-development partnerships with larger pharmaceutical companies, or an eventual acquisition. Its only documented financing is a $54 million Series A closed in October 2018, led by Versant Ventures with Forbion Capital Partners and SR One as co-investors. Leadership consists of Founder Samie Jaffray and CEO Lee Babiss. The company has no disclosed revenue, pricing, partnerships, or commercial milestones in the available source material.

Gotham Therapeutics firmographics

Firmographics
Name
Gotham Therapeutics
Website
https://gothamtx.com
Company type
Private
Founded year
2017
Headcount range
1–10 employees
Short description
Gotham Therapeutics is a preclinical-stage, New York-based biotechnology company founded in 2017 that is developing small-molecule drugs targeting RNA-modifying enzymes (epitranscriptomics) for therapeutic use.
Ownership category
akta.pro rank

Gotham Therapeutics industry classification

Industry
Product category
Epitranscriptomic Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Epitranscriptomic drug discovery
  • RNA-modifying enzyme inhibitors
  • Small molecule therapeutics
  • Novel drug class
  • Biotech drug development

Where Gotham Therapeutics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Gotham Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Gotham Therapeutics product offering

Product offering

Core offering

Gotham Therapeutics is a biotechnology company focused on discovering a novel drug class that targets the epitranscriptomics machinery — the enzymes and readers responsible for chemical modifications of RNA. The company identifies and develops small-molecule therapeutics against RNA-modifying enzymes for the treatment of disease, primarily operating in early-stage drug discovery.

Product overview

The source data does not relate to Gotham Therapeutics. The domain gothamtx.com is a slot gambling review content website acquired by X41 Group in 2024, previously associated with a Therapeutics company of the same name. No product or service offerings for Gotham Therapeutics were found in the source material.

Differentiator

Problem solved

Functional benefit

Companies that use Gotham Therapeutics

Customer profile

Ideal customer profiles1 record

Gotham Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Gotham Therapeutics partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights1 record

Gotham Therapeutics competitors and assessment

Company assessment

Direct peers

  • Accent Therapeutics: Direct competitor also developing small-molecule inhibitors of RNA-modifying enzymes (notably METTL3 and other m6A writers), with a substantially larger Series B/C financing base.
  • Storm Therapeutics: UK-based epitranscriptomics company developing first-in-class small molecules against RNA-modifying enzymes, the closest international analogue to Gotham's scientific focus.
  • Twentyeight-Seven Therapeutics: Targets RNA-modifying proteins (e.g., METTL3) for cancer therapy; one of the original entrants into the small-molecule epitranscriptomics space.
  • 858 Therapeutics: Emerging epitranscriptomics player focused on small-molecule modulators of RNA-modifying enzymes in oncology and other indications.

Emerging players

  • Skyhawk Therapeutics: Develops small molecules that modulate RNA splicing and RNA biology; overlapping modality of small-molecule RNA targeting with multiple pharma partnerships.
  • HiberCell: Pursues therapeutic modulation of RNA modifications and biomolecular condensates in cancer; partial mechanistic overlap with Gotham's epitranscriptomic strategy.
  • Arrakis Therapeutics: Discovers small molecules that target RNA structures and RNA-protein interactions; complementary rather than identical mechanism but competing for the same RNA-targeting BD budget.
  • Expansion Therapeutics: Develops small-molecule RNA-targeting therapeutics, primarily for repeat-expansion disorders; comparable RNA-biology drug-discovery platform approach.

Broad incumbents

  • Omega Therapeutics: Public epigenomic programming company using engineered mRNA-encoded transcription factors; a broader incumbent in the gene-expression modulation space adjacent to epitranscriptomics.
  • Foghorn Therapeutics: Public chromatin-regulation company targeting dysregulated gene-expression machinery in cancer; adjacent to Gotham's RNA-biology strategy via shared interest in gene-expression modulators.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Gotham Therapeutics social profiles

Digital presence

Gotham Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gotham Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Gotham Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gotham Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gotham Therapeutics

What does Gotham Therapeutics do?

Gotham Therapeutics is a biotechnology company focused on discovering a novel drug class that targets the epitranscriptomics machinery — the enzymes and readers responsible for chemical modifications of RNA. The company identifies and develops small-molecule therapeutics against RNA-modifying enzymes for the treatment of disease, primarily operating in early-stage drug discovery.

When was Gotham Therapeutics founded?

Gotham Therapeutics was founded in 2017. It employs 1 to 10 people.

Where is Gotham Therapeutics based?

Gotham Therapeutics is headquartered in New York, United States, in the North America region.

Who are Gotham Therapeutics's main competitors?

Direct peers on record are Accent Therapeutics, Storm Therapeutics, Twentyeight-Seven Therapeutics and 858 Therapeutics. Emerging players are Skyhawk Therapeutics, HiberCell, Arrakis Therapeutics and Expansion Therapeutics. Broad incumbents are Omega Therapeutics and Foghorn Therapeutics.

Does Gotham Therapeutics have an API?

No public API is recorded for Gotham Therapeutics.

What industry is Gotham Therapeutics in?

Gotham Therapeutics's product category is Epitranscriptomic Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals